NCT02884908View on ClinicalTrials.gov

Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

January 19, 2022

Study Completion Date

January 19, 2022

Conditions
PTSDAlcohol Use Disorder
Interventions
DRUG

Pregabalin plus BBCET

Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment

OTHER

Placebo plus BBCET

Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment

Trial Locations (1)

21228

University of Maryland School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT02884908 - Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD | Biotech Hunter | Biotech Hunter